Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1

Cellular Immunology

Volumn 271, Issue 2, 2011, Pages 392-400

  Zhao, Dan ^a,b   Amria, Shereen ^a,b   Hossain, Azim ^a,b   Sundaram, Kumaran ^b   Komlosi, Peter ^b   Nagarkatti, Mitzi ^c   Haque, Azizul ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bryostatin 1; Cathepsins; CD4+ T cells; Costimulatory molecules (CD80 86); HLA class II molecules; Matrix metalloproteinase 9; Melanoma

Indexed keywords

B7 ANTIGEN; BRYOSTATIN 1; CATHEPSIN; CD86 ANTIGEN; CLASS II TRANSACTIVATOR PROTEIN; GELATINASE B; HLA ANTIGEN CLASS 2; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INTERACTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MELANOMA CELL; MOLECULAR RECOGNITION; PRIORITY JOURNAL; SKIN CARCINOGENESIS; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ANTIGEN PRESENTATION; ANTIGENS, CD80; ANTIGENS, CD86; BASE SEQUENCE; BRYOSTATINS; CATHEPSIN B; CATHEPSIN D; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; ENZYME INHIBITORS; ENZYME PRECURSORS; HLA-D ANTIGENS; HUMANS; MATRIX METALLOPROTEINASE 9; MELANOMA; NUCLEAR PROTEINS; RNA, NEOPLASM; TRANS-ACTIVATORS;

EID: 80054012798     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.08.007     Document Type: Article

References (61)

1. Kirkwood J.M., Tarhini A.A., Panelli M.C., et al. Next generation of immunotherapy for melanoma. J. Clin. Oncol. 2008, 26(20):3445-3455.
2. Nelson A.A., Tsao H. Melanoma and genetics. Clin. Dermatol. 2009, 27(1):46-52.
3. Gruber F., Kastelan M., Brajac I., et al. Molecular and genetic mechanisms in melanoma. Coll. Antropol. 2008, 32(Suppl. 2):147-152.
4. Zigler M., Villares G.J., Lev D.C., Melnikova V.O., Bar-Eli M. Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am. J. Clin. Dermatol. 2008, 9(5):307-311.
5. Haque M.A., Li P., Jackson S.K., et al. Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes. J. Exp. Med. 2002, 195(10):1267-1277.
6. Held G., Neumann F., Sturm C., et al. Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells. Int. J. Cancer 2008, 123(8):1841-1847.
7. Robila V., Ostankovitch M., Altrich-Vanlith M.L., et al. MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes. J. Immunol. 2008, 181(11):7843-7852.
8. Vyas J.M., Van der Veen A.G., Ploegh H.L. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 2008, 8(8):607-618.
9. Dickgreber N., Stoitzner P., Bai Y., et al. Targeting antigen to MHC class II molecules promotes efficient cross-presentation and enhances immunotherapy. J. Immunol. 2009, 182(3):1260-1269.
10. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr. Opin. Genet. Dev. 2008, 18(1):11-18.
11. Haque A., Blum J.S. New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases. J. Biol. Regul. Homeost. Agents 2005, 19(3-4):93-104.
12. Godefroy E., Scotto L., Souleimanian N.E., et al. Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clin. Immunol. 2006, 121(1):54-62.
13. Dissanayake S.K., Thompson J.A., Bosch J.J., et al. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res. 2004, 64(5):1867-1874.
14. Bosch J.J., Thompson J.A., Srivastava M.K., et al. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res. 2007, 67(9):4499-4506.
15. Anichini A., Mortarini R., Nonaka D., et al. Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on cancer stage III and IV melanoma patients. Cancer Res. 2006, 66(12):6405-6411.
16. Bernsen M.R., Hakansson L., Gustafsson B., et al. On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases. Br. J. Cancer 2003, 88(3):424-431.
17. Linsley P.S., Clark E.A., Ledbetter J.A. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc. Natl. Acad. Sci. USA 1990, 87(13):5031-5035.
18. Ariza M.E., Ramakrishnan R., Singh N.P., Chauhan A., Nagarkatti P.S., Nagarkatti M. Bryostatin-1, a naturally occurring antineoplastic agent, acts as a toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells. J. Biol. Chem. 2011, 286(1):24-34.
19. Stone R.M., Sariban E., Pettit G.R., Kufe D.W. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 1988, 72(1):208-213.
20. Kudinov Y., Wiseman C.L., Kharazi A.I. Phorbol myristate acetate and bryostatin 1 rescue IFN-gamma inducibility of MHC class II molecules in LS1034 colorectal carcinoma cell line. Cancer Cell Int. 2003, 3:4.
21. Do Y., Mainali E., Nagarkatti P.S., Nagarkatti M. Bryostatin-1 in combination with calcium ionophore promotes the maturation of human umbilical cord-blood monocyte-derived dendritic cells capable of activating neonatal alloreactive T cells. Cell. Immunol. 2004, 231(1-2):8-13.
22. Kennedy M.J., Prestigiacomo L.J., Tyler G., May W.S., Davidson N.E. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res. 1992, 52(5):1278-1283.
23. Dale I.L., Bradshaw T.D., Gescher A., Pettit G.R. Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells. Cancer Res. 1989, 49(12):3242-3245.
24. Hornung R.L., Pearson J.W., Beckwith M., Longo D.L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res. 1992, 52(1):101-107.
25. O'Donnell P.W., Haque A., Klemsz M.J., Kaplan M.H., Blum J.S. Cutting edge: induction of the antigen-processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells Is STAT1-dependent but CIITA-independent. J. Immunol. 2004, 173(2):731-735.
26. Haque A., Das A., Hajiaghamohseni L.M., Younger A., Banik N.L., Ray S.K. Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human malignant glioblastoma T98G and U87MG cells. Cancer Immunol. Immunother. 2007, 56(5):615-625.
27. Younger A.R., Amria S., Jeffrey W.A., et al. HLA class II antigen presentation by prostate cancer cells. Prostate Cancer Prostatic Dis. 2008, 11(4):334-341.
28. Haque A., Hajiaghamohseni L.M., Li P., Toomy K., Blum J.S. Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells. Cell. Immunol. 2007, 249(1):20-29.
29. Amria S., Cameron C., Stuart R., Haque A. Defects in HLA class II antigen presentation in B-cell lymphomas. Leuk. Lymphoma 2008, 49(2):353-355.
30. Haque M.A., Hawes J.W., Blum J.S. Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition. J. Immunol. 2001, 166(7):4543-4551.
31. Amria S., Hajiaghamohseni L.M., Harbeson C., et al. HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell recognition. Eur. J. Immunol. 2008, 38(7):1961-1970.
32. Goldstein O.G., Hajiaghamohseni L.M., Amria S., Sundaram K., Reddy S.V., Haque A. Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma. Cancer Immunol. Immunother. 2008, 57(10):1461-1470.
33. Komlosi P., Banizs B., Fintha A., Steele S., Zhang Z.R., Bell P.D. Oscillating cortical thick ascending limb cells at the juxtaglomerular apparatus. J. Am. Soc. Nephrol. 2008, 19(10):1940-1946.
34. Godet Y., Bonnin A., Guilloux Y., et al. A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients. Cancer Immunol. Immunother. 2009, 58(2):271-280.
35. Pandolfi F., Cianci R., Lolli S., et al. Strategies to overcome obstacles to successful immunotherapy of melanoma. Int. J. Immunopathol. Pharmacol. 2008, 21(3):493-500.
36. Walker E.B., Haley D., Petrausch U., et al. Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization. Clin. Cancer Res. 2008, 14(16):5270-5283.
37. Schuchter L.M., Esa A.H., May S., Laulis M.K., Pettit G.R., Hess A.D. Successful treatment of murine melanoma with bryostatin 1. Cancer Res. 1991, 51(2):682-687.
38. Tuttle T.M., Bethke K.P., Inge T.H., McCrady C.W., Pettit G.R., Bear H.D. Bryostatin 1-activated T cells can traffic and mediate tumor regression. J. Surg. Res. 1992, 52(6):543-548.
39. Thompson C.H., Macaulay V.M., O'Byrne K.J., et al. Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. Br. J. Cancer 1996, 73(10):1161-1165.
40. Do Y., Hegde V.L., Nagarkatti P.S., Nagarkatti M. Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells. Cancer Res. 2004, 64(18):6756-6765.
41. Thompson J.A., Dissanayake S.K., Ksander B.R., Knutson K.L., Disis M.L., Ostrand-Rosenberg S. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res. 2006, 66(2):1147-1154.
42. Rodriguez T., Mendez R., Del Campo A., et al. Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics 2007, 59(2):123-133.
43. Battle T.E., Frank D.A. STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to bryostatin 1. Blood 2003, 102(8):3016-3024.
44. Nikkola J., Vihinen P., Vuoristo M.S., Kellokumpu-Lehtinen P., Kahari V.M., Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin. Cancer Res. 2005, 11(14):5158-5166.
45. Vaisanen A.H., Kallioinen M., Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum. Pathol. 2008, 39(3):377-385.
46. Zhang T., Maekawa Y., Hanba J., et al. Lysosomal cathepsin B plays an important role in antigen processing, while cathepsin D is involved in degradation of the invariant chain inovalbumin-immunized mice. Immunology 2000, 100(1):13-20.
47. Norton D.L., Haque A. Insights into the role of GILT in HLA class II antigen processing and presentation by melanoma. J. Oncol. 2009, 2009:142959.
48. Vasiljeva O., Turk B. Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion. Biochimie 2008, 90(2):380-386.
49. Podgorski I., Sloane B.F. Cathepsin B and its role(s) in cancer progression. Biochem. Soc. Symp. 2003, 70:263-276.
50. Roshy S., Sloane B.F., Moin K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev. 2003, 22(2-3):271-286.
51. Beaujouin M., Prebois C., Derocq D., et al. Pro-cathepsin D interacts with the extracellular domain of the beta chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth. J. Cell Sci. 2010, 123(Pt 19):3336-3346.
52. Stremmel C., Greenfield E.A., Howard E., Freeman G.J., Kuchroo V.K. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J. Exp. Med. 1999, 189(6):919-930.
53. Chaperot L., Plumas J., Jacob M.C., et al. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. Exp. Hematol. 1999, 27(3):479-488.
54. Anderson R.C., Anderson D.E., Elder J.B., et al. Lack of B7 expression not human leukocyte antigen expression, facilitates immune evasion by human malignant gliomas. Neurosurgery 2007, 60(6):1129-1136. (discussion 1136).
55. Thomas I.J., Petrich de Marquesini L.G., Ravanan R., et al. CD86 has sustained costimulatory effects on CD8 T cells. J. Immunol. 2007, 179(9):5936-5946.
56. Srivastava M.K., Bosch J.J., Wilson A.L., Edelman M.J., Ostrand-Rosenberg S. MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells. Int. J. Cancer 2010, 127(11):2612-2621.
57. Chai J.G. Cancer vaccination reprograms regulatory T cells into helper CD4 T cells to promote antitumor CD8 T-cell responses. Immunotherapy 2011, 3(5):601-604.
58. Pettit G.R., Kamano Y., Herald C.L. Antineoplastic agents, 118. Isolation and structure of bryostatin 9. J. Nat. Prod. 1986, 49(4):661-664.
59. Ko H.M., Kang J.H., Jung B., et al. Critical role for matrix metalloproteinase-9 in platelet-activating factor-induced experimental tumor metastasis. Int. J. Cancer 2007, 120(6):1277-1283.
60. Redondo P., Lloret P., Idoate M., Inoges S. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin. Exp. Dermatol. 2005, 30(5):541-545.
61. Johnson B.D., Yan X., Schauer D.W., Orentas R.J. Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. Cell. Immunol. 2003, 222(1):15-26.